The EVAPORATE study is being conducted on Amarin's (AMRN) Vascepa by a team of non-Amarin affiliated researchers led by Dr Matthew Budoff, MD, professor of medicine at David Geffen School of Medicine at UCLA. The "purpose of this study is to determine whether the addition of IPE 4g/d will result in a greater change from baseline in plaque volume measured by serial multidetector computed tomography (MDCT) than placebo in statin-treated patients." IPE is Icosapent Ethyl or Vascepa. 4g/d is the same dose as used in the REDUCE-IT trial.
We read through the abstract presented at